NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
Clinical Trials
368 trialsNCT07342517 2026-03-17
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07284953 2026-03-13
PuraBond
The Royal Wolverhampton Hospitals NHS Trust
Phase NA Withdrawn
NCT04243473 2026-03-03
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Withdrawn
NCT05014295 2026-02-24
Patient Recall of Cancer Screening and Diagnosis
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT03027986 2026-02-17
PROTOMEN
University Hospital, Rouen
Phase NA Withdrawn
NCT05487859 2026-02-17
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06603155 2025-12-19
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Duke University
Phase NA Withdrawn
NCT07084909 2025-12-10
HARRIER
Lantheus Medical Imaging
Phase 2/3 Withdrawn
NCT03274778 2025-11-18
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Oncology Institute of Southern Switzerland
Phase NA Withdrawn
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06392841 2025-10-20
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04645810 2025-10-15
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
University of Rochester
Phase NA Withdrawn
NCT05046782 2025-09-30
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT02869282 2025-09-17
CHEMOPROST
Institut Bergonié
Withdrawn
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT06940804 2025-07-02
AVENTURINE
BioNTech SE
Phase 2 Withdrawn
NCT04688333 2025-06-26
iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
City of Hope Medical Center
Withdrawn
NCT06816017 2025-06-16
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Hoffmann-La Roche
Phase 1 Withdrawn
NCT05687721 2025-06-15
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
VA Office of Research and Development
Phase 1/2 Withdrawn
NCT02671552 2025-05-02
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery
Thomas Jefferson University
Phase EARLY_PHASE1 Withdrawn
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT03581500 2025-04-23
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05815316 2025-04-13
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
IRCCS San Raffaele
Phase 2 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT06422312 2025-04-04
A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.
Guangzhou Red Pine Medical Instrument Co., Ltd.
Phase NA Withdrawn
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT04889495 2025-03-19
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer
Withdrawn
NCT06457854 2025-03-12
PROCeed-BR
AstraZeneca
Withdrawn
NCT03197571 2025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT02608359 2025-02-03
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
Johnson & Johnson Private Limited
Withdrawn
NCT02905201 2025-02-03
TOGETHER
Janssen Research & Development, LLC
Withdrawn
NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT04495959 2025-01-08
Dynamic Whole Body PET/ MRI
British Columbia Cancer Agency
Withdrawn
NCT05568537 2025-01-03
Prostate MRI and Pylarify PSMA PET/CT
Corewell Health East
Phase 4 Withdrawn
NCT01350180 2024-12-10
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT02588404 2024-12-10
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT05418387 2024-11-25
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
University of Arizona
Phase NA Withdrawn
NCT06390111 2024-11-22
ABLE-42
Ferring Pharmaceuticals
Phase 4 Withdrawn
NCT02588846 2024-11-18
KOALA
Royal North Shore Hospital
Phase NA Withdrawn
NCT03990194 2024-10-31
LEPTO
RECORDATI GROUP
Withdrawn
NCT06218667 2024-10-31
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn